LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 401–500 of 1,004
MicroRNAs, the DNA damage response and cancer
Wouters, M. D., van Gent, D. C., Hoeijmakers, J. H. J., & Pothof, J. (2011) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2011.03.012 · Cited by 102
“However, the main process that occurs within P-bodies is microRNA-mediated mRNA degradation [78, 79].”
BackgroundGambari, R., Fabbri, E., Borgatti, M., Lampronti, I., Finotti, A., Brognara, E., Bianchi, N., Manicardi, A., Marchelli, R., & Corradini, R. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.08.007 · Cited by 109
A MicroRNA Guide for Clinicians and Basic Scientists: Background and Experimental Techniques
Bernardo, B. C., Charchar, F. J., Lin, R. C. Y., & McMullen, J. R. (2011) · Heart Lung and Circulation · doi:10.1016/j.hlc.2011.11.002 · Cited by 115
MicroRNAs: Regulating a Change of Heart
Barringhaus, K. G., & Zamore, P. D. (2009) · Circulation · doi:10.1161/circulationaha.107.715839 · Cited by 105
Epigenetics and the nervous system
Mehler, M. F. (2008) · Annals of Neurology · doi:10.1002/ana.21595 · Cited by 99
Chen, L.-L., Zhang, Z., Yi, Z.-B., & Li, J.-J. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.150 · Cited by 104
“…expression by binding directly to the 30 untranslated region (30-UTR) of corresponding target messenger RNAs (mRNAs) in a sequence-specific manner, which induces mRNA degradation or protein translation repression (Ambros, 2004; Bartel, 2004; Elmén et al, 2008; Kota et al, 2009; Yates et al, 2013).”
BackgroundMicroRNAs: emerging roles in lipid and lipoprotein metabolism
Sacco, J., & Adeli, K. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283534c9f · Cited by 96
“A role for miR-122 in lipid metabolism was revealed in knockdown studies [26,27].”
BackgroundMicroRNAs and Diabetic Complications
Natarajan, R., Putta, S., & Kato, M. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9368-5 · Cited by 99
“Locked nucleic acid (LNA) modified antimiRNAs (antimiR) have been shown to be very effective for inhibiting miRNAs (36,83,84).”
BackgroundChemical Modification of Oligonucleotides for Therapeutic, Bioanalytical and other Applications
Bell, N. M., & Micklefield, J. (2009) · ChemBioChem · doi:10.1002/cbic.200900341 · Cited by 104
Roles of micro RNA s in psoriasis: Immunological functions and potential biomarkers
Liu, Q., Wu, D., Han, L., Deng, J., Zhou, L., He, R., Lu, C., & Mi, Q. (2017) · Experimental Dermatology · doi:10.1111/exd.13249 · Cited by 101
The Emerging Role of MicroRNAs in the Regulation of Gene Expression by Nutrients
García-Segura, L., Pérez-Andrade, M., & Miranda-Ríos, J. (2013) · Lifestyle Genomics · doi:10.1159/000345826 · Cited by 102
Norman, K., & Sarnow, P. (2009) · Journal of Virology · doi:10.1128/jvi.01156-09 · Cited by 103
Self-citationIntegrating the MicroRNome into the Study of Lung Disease
Nana-Sinkam, S. P., Hunter, M. G., Nuovo, G. J., Schmittgen, T. D., Gelinas, R., Galas, D., & Marsh, C. B. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200807-1042pp · Cited by 101
Ruggeri, C., Gioffré, S., Achilli, F., Colombo, G. I., & D’Alessandra, Y. (2018) · Heart Failure Reviews · doi:10.1007/s10741-017-9653-0 · Cited by 104
“The use of systemically administered antimiRs in exploring miRNA function in rodents and primates has been previously proposed [51] , thus the article by Tony and coworkers supports the potential of these compounds as a new class of therapeutics for disease-associated miRNAs.”
microRNAs in the onset and development of cardiovascular disease
Vickers, K. C., Rye, K., & Tabet, F. (2013) · Clinical Science · doi:10.1042/cs20130203 · Cited by 107
“miR-122 was the first miRNA to be identified as having an important role in the regulation of lipid metabolism [48,49].”
BackgroundA statin‐regulated microRNA represses human c‐Myc expression and function
Takwi, A. A. L., Li, Y., Becker Buscaglia, L. E., Zhang, J., Choudhury, S., Park, A. K., Liu, M., Young, K. H., Park, W., Martin, R. C. G., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201101045 · Cited by 100
“Experimental modified oligonucleotides tested in rodents and primates are generally longer than 15 bases (MW (cid:1) 5000Da) (Elmen et al, 2008; Krutzfeldt et al, 2005).”
Circulating microRNA-122 as a potential biomarker for liver injury
Ding, J. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.838 · Cited by 94
“miRNA-122 is the most abundant miRNA species in the liver, accounting for ~70% of the total miRNA population, and is essential for cholesterol and lipid metabolism (12-15).”
BackgroundPeptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA
Järver, P., Coursindel, T., Andaloussi, S. E., Godfrey, C., Wood, M. J. A., & Gait, M. J. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.18 · Cited by 113
“19,20,35,82,83 Thus it seems unlikely that peptide-mediated delivery will be of value for such oligonucleotide types.”
MicroRNA: a new frontier in kidney and blood pressure research
Liang, M., Liu, Y., Mladinov, D., Cowley, A. W., Trivedi, H., Fang, Y., Xu, X., Ding, X., & Tian, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00045.2009 · Cited by 105
SUZUKI, S., YOKOBORI, T., TANAKA, N., SAKAI, M., SANO, A., INOSE, T., SOHDA, M., NAKAJIMA, M., MIYAZAKI, T., KATO, H., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.1831 · Cited by 100
“Although miRNAs show signs of being a new class of targets for therapeutic applications (37), the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge (38,39).”
Lorente‐Cebrián, S., González‐Muniesa, P., Milagro, F. I., & Martínez, J. A. (2019) · Clinical Science · doi:10.1042/cs20180890 · Cited by 127
Chai, C., Rivkin, M., Berkovits, L., Simerzin, A., Zorde-Khvalevsky, E., Rosenberg, N., Klein, S., Yaish, D., Durst, R., Shpitzen, S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.08.013 · Cited by 100
Vogel, P., Schneider, M. F., Wettengel, J., & Stafforst, T. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201402634 · Cited by 107
PEGylated reduced graphene oxide as a superior ssRNA delivery system.
Zhang, L.-M., Wang, Z.-L., Lu, Z., Shen, H., Huang, J., Zhao, Q., Liu, M., He, N., & Zhang, Z. (2013) · Journal of materials chemistry. B · doi:10.1039/c2tb00096b · Cited by 100
Cleavage of RNA phosphodiester bonds by small molecular entities: a mechanistic insight
Lönnberg, H. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00486c · Cited by 123
MicroRNAs as new therapeutic targets and tools in cancer
Gandellini, P., Profumo, V., Folini, M., & Zaffaroni, N. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.550878 · Cited by 106
“infusions over 5 days) resulted in a dose-dependent and long-lasting reduction of liver miR-122 levels and in a decrease in plasma cholesterol levels for up to 3 months [40].”
BackgroundHorwich, M. D., & Zamore, P. D. (2008) · Nature Protocols · doi:10.1038/nprot.2008.145 · Cited by 105
Biological Activity and Biotechnological Aspects of Locked Nucleic Acids
Lundin, K. E., Højland, T., Hansen, B. R., Persson, R., Bramsen, J. B., Kjems, J., Koch, T., Wengel, J., & Smith, C. I. E. (2013) · Advances in genetics · doi:10.1016/b978-0-12-407676-1.00002-0 · Cited by 123
Regulating the regulators: mechanisms controlling the maturation of microRNAs
Ding, X. C., Weiler, J., & Großhans, H. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.09.006 · Cited by 101
Experimental identification of microRNA targets
Ørom, U. A., & Lund, A. H. (2009) · Gene · doi:10.1016/j.gene.2009.11.008 · Cited by 107
MiRNAs and Cancer: Key Link in Diagnosis and Therapy
Shi, Y., Liu, Z., Lin, Q., Luo, Q., Cen, Y., Li, J., Fang, X., & Gong, C. (2021) · Genes · doi:10.3390/genes12081289 · Cited by 132
“Moreover, LNA-modified antimiRs have remarkable therapeutic response in mouse models [86,87].”
BackgroundMicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs.
Bhardwaj, A., Singh, S., & Singh, A. P. (2010) · PubMed · doi:10.4255/mcpharmacol.10.27 · Cited by 93
“Nonetheless, the use of LNA (locked nucleic acid) technology has presented a breakthrough and a phase I clinical trial with LNA-antimiR-122 has already been initiated based on exciting preliminary data in non-human primates (50).”
Squamous cell carcinoma of the skin shows a distinct microRNA profile modulated by UV radiation.
Dziunycz, P. J., Iotzova-Weiss, G., Eloranta, J., Läuchli, S., Hafner, J., French, L., & Hofbauer, G. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.169 · Cited by 97
“Importantly, the successful use of antagomirs to silence microRNAs in mice and nonhuman primates suggests a possible therapeutic use of microRNAs (Elmen et al., 2008; Krutzfeldt et al., 2005).”
BackgroundThe road toward microRNA therapeutics
Seto, A. G. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.03.003 · Cited by 95
Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology
Weng, Y., Huang, Q., Li, C., Yang, Y., Wang, X., Yu, J., Huang, Y., & Liang, X.-J. (2020) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.12.004 · Cited by 107
MiRNA inhibition in tissue engineering and regenerative medicine
Beavers, K. R., Nelson, C. E., & Duvall, C. L. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.006 · Cited by 108
Chen, Z. B., Shentu, T., Wen, L., Johnson, D. A., & Shyy, J. Y.-J. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4803 · Cited by 105
“The recently developed antagomirs such as LNAs show great promise as therapeutic agents (35,71).”
BackgroundmiRNAs: roles and clinical applications in vascular disease
Jamaluddin, M. S., Weakley, S. M., Zhang, L., Kougias, P., Lin, P. H., Yao, Q. C., & Chen, C. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.103 · Cited by 102
Kojima, S., Gatfield, D., Esau, C. C., & Green, C. B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011264 · Cited by 92
“Blocking miR-122 expression leads to the reduction of plasma cholesterol and triglyceride levels in both rodents and primates, [15,17,18,19].”
BackgroundChakraborty, C., Sharma, A. R., Sharma, G., Sarkar, B. K., & Lee, S.-S. (2018) · Oncotarget · doi:10.18632/oncotarget.24309 · Cited by 108
“It formed a configuration of a heteroduplexes, connecting LNA-anti-miR and miR122 [41].”
BackgroundSmall molecules targeting microRNA for cancer therapy: Promises and obstacles
Wen, D., Danquah, M. K., Chaudhary, A., & Mahato, R. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.011 · Cited by 110
Umbach, J. L., Yen, H., Poon, L. L. M., & Cullen, B. R. (2010) · mBio · doi:10.1128/mbio.00204-10 · Cited by 101
“(35) is that introduction of an antisense locked nucleic acid (LNA) oligonucleotide (36) complementary to the HA segment leRNA inhibits HA vRNA synthesis yet had little or no effect on HA mRNA or cRNA transcription, thus suggesting that leRNAs might play a critical role in virus genome replication, perhaps by triggeri…”
BackgroundThe role of microRNAs in coronary artery disease: From pathophysiology to diagnosis and treatment
Economou, E. K., Oikonomou, E. K., Siasos, G., Παπαγεωργίου, Ν., Tsalamandris, S., Mourouzis, K., Papaioannou, S., & Tousoulis, D. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.037 · Cited by 106
Antitumor effect of miR-197 targeting in p53 wild-type lung cancer
Fiori, M. E., Barbini, C., Haas, T. L., Marroncelli, N., Patrizii, M., Biffoni, M., & Maria, R. D. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.6 · Cited by 99
Brønnum, H., Andersen, D. C., Schneider, M., Sandberg, M. B., Eskildsen, T., Nielsen, S. B., Kalluri, R., & Sheikh, S. P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056280 · Cited by 92
“The applied anti-miRs were designed in accordance with previously validated Locked nucleic acid-based anti-miRs [31] (Scramble, 59-+T*G*+T*A*A*+C*+A*C*G*+T*C*+T*A*+T*+A-39; anti-miR-21, 59+T*C*+A*G*T*+C*+T*G*A*+T*A*+A*G*+C*+T 39;+denotes MiRNA Regulation of Cardiac Fibrogenic EMT”
MethodKambara, H., Fukuhara, T., Shiokawa, M., Ono, C., Ohara, Y., Kamitani, W., & Matsuura, Y. (2011) · Journal of Virology · doi:10.1128/jvi.06242-11 · Cited by 94
“C indicates LNA methylcytosine) (14) were purchased from Gene Design”
MethodRegulation of Heme Oxygenase-1 Protein Expression by miR-377 in Combination with miR-217
Beckman, J. D., Chen, C., Nguyen, J., Thayanithy, V., Subramanian, S., Steer, C. J., & Vercellotti, G. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.148726 · Cited by 87
Signal transduction therapy of cancer
Levitzki, A., & Klein, S. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.04.001 · Cited by 103
Tian, N., Cao, Z., & Zhang, Y. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1419-7 · Cited by 93
Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure
Mortimer, S., & Doudna, J. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt075 · Cited by 93
MicroRNA Regulation of Cholesterol Metabolism
Rotllán, N., & Fernandez-Hernando, C. F. (2012) · Cholesterol · doi:10.1155/2012/847849 · Cited by 94
“This lack of a mechanistic understanding of the effects of miR-122 on cholesterol homeostasis, and the possibilities of other adverse consequences as the decline levels of HDL, both in mice and in nonhuman primates [11, 23, 62], and hepatocellular carcinoma, has also dampened the enthusiasm for the development of miR-…”
BackgroundResultXu, Q.-F., Seeger, F., Castillo, J., Iekushi, K., Boon, R., Farcas, R., Manavski, Y., Li, Y.-G., Assmus, B., Zeiher, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.02.033 · Cited by 93
MicroRNAs: novel therapeutic targets in neurodegenerative diseases
Roshan, R., Ghosh, T., Scaria, V., & Pillai, B. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.009 · Cited by 94
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering
Bramsen, J. B., & Kjems, J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00154 · Cited by 92
Strategies to use microRNAs as therapeutic targets
Krützfeldt, J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.07.004 · Cited by 67
Polymer Nanoparticle-Mediated Delivery of MicroRNA Inhibition and Alternative Splicing
Cheng, C. J., & Saltzman, W. M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300081s · Cited by 98
New Insights into Structure and Replication of the Hepatitis C Virus and Clinical Implications
Poenisch, M., & Bartenschlager, R. (2010) · Seminars in liver disease (Print) · doi:10.1055/s-0030-1267535 · Cited by 92
Role of haem oxygenase-1 in microbial host defence
Chung, S. W., Hall, S. R., & Perrella, M. A. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2008.01261.x · Cited by 96
Molecular Pathogenesis of Ischemic and Hemorrhagic Strokes: Background and Therapeutic Approaches
Maida, C. D., Norrito, R. L., Rizzica, S., Mazzola, M., Scarantino, E. R., & Tuttolomondo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126297 · Cited by 131
MicroRNA based theranostics for brain cancer: basic principles
Petrescu, G. E. D., Sabo, A. A., Torsin, L. I., Călin, G. A., & Dragomir, M. P. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1180-5 · Cited by 113
Circulating microRNAs in Huntington’s disease: Emerging mediators in metabolic impairment
Díez‐Planelles, C., Sánchez-Lozano, P., Crespo, M. C., Gil‐Zamorano, J., Ribacoba, R., González, N., Suárez, E., Martínez‐Descals, A., Martínez‐Camblor, P., Álvarez, V., et al. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.005 · Cited by 100
Xiao, L., Rao, J. N., Cao, S., Liu, L., Chung, H. K., Zhang, Y., Zhang, J., Liu, Y., Gorospe, M., & Wang, J. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-10-0703 · Cited by 117
“RNA-FISH assay The RNA-FISH assay was performed with the ISH Optimization Kit from Exiqon (Vedbaek, Denmark) as described (Elmen et al., 2008).”
MethodRole of MicroRNAs in NAFLD/NASH
Szabó, G., & Csák, T. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4002-4 · Cited by 99
“It is known to regulate genes involved in fatty acid biosynthesis, and administration of this miRNA antagonist in mice resulted in reduced levels of plasma cholesterol, increased hepatic fatty acid oxidation, and decreased synthesis of hepatic fatty acid and cholesterol [45, 46].”
Hosin, A. A., Prasad, A., Viiri, L. E., Davies, A. H., & Shalhoub, J. (2014) · Journal of Vascular Research · doi:10.1159/000368193 · Cited by 53
Ge, Q., Brichard, S., Yi, X., & Li, Q. (2014) · Journal of Immunology Research · doi:10.1155/2014/987285 · Cited by 102
“This was achieved without significant adverse reactions or hepatic toxicity [89, 90].”
BackgroundTorres, A. G., Fabani, M. M., Vigorito, E., & Gait, M. J. (2011) · RNA · doi:10.1261/rna.2533811 · Cited by 108
Low Vitamin B12 and Lipid Metabolism: Evidence from Pre-Clinical and Clinical Studies
Boachie, J., Adaikalakoteswari, A., Samavat, J., & Saravanan, P. (2020) · Nutrients · doi:10.3390/nu12071925 · Cited by 130
“In humans, miRNA-122 is largely expressed in hepatocytes but under expressed in NASH [104] and therefore is proposed to be the potential target for treatment of dyslipidemia [105] and high cholesterol [106].”
BackgroundKokil, G. R., Veedu, R. N., Ramm, G. A., Prins, J. B., & Parekh, H. S. (2015) · Chemical Reviews · doi:10.1021/cr5002832 · Cited by 111
MicroRNAs in the DNA Damage/Repair Network and Cancer
Tessitore, A., Cicciarelli, G., Vecchio, F. D., Gaggiano, A., Verzella, D., Fischietti, M., Vecchiotti, D., Capece, D., Zazzeroni, F., & Alesse, E. (2014) · International Journal of Genomics · doi:10.1155/2014/820248 · Cited by 107
“…overexpression of N-myc, a gene frequently amplified in neuroblastoma, was able to induce miR-421 expression with consequent ATM downregulation, suggesting a correlation between N-myc-mediated oncogenesis and the network involving miRNAs and molecules working in the DNA damage/repair machinery.”
MicroRNAs in Atrial Fibrillation: from Expression Signatures to Functional Implications
van den Berg, N. W. E., Kawasaki, M., Berger, W. R., Neefs, J., Meulendijks, E. R., Tijsen, A. J., & de Groot, J. R. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6736-z · Cited by 101
“Before miRNA-based therapy is implemented in clinical practice, concerns about the safety of miRNA therapeutics in humans need to be overcome [21, 131, 133].”
BackgroundLi, M., Li, J., Ding, X., He, M., & Cheng, S. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9194-0 · Cited by 176
“Administration of LNA-antimir to mice effectively blocks liver-specific miR-122 expression in vivo (112).”
BackgroundmicroRNAs and Neurodegenerative Diseases
Qiu, L., Tan, E., & Zeng, L. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-22671-2_6 · Cited by 108
MicroRNA as a Potential Therapeutic Molecule in Cancer
Szczepanek, J., Skorupa, M., & Tretyn, A. (2022) · Cells · doi:10.3390/cells11061008 · Cited by 88
Saleh, R., Toor, S. M., Nair, V. S., & Elkord, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01469 · Cited by 121
microRNA in Cardiovascular Aging and Age-Related Cardiovascular Diseases
de Lucia, C., Komici, K., Borghetti, G., Femminella, G. D., Bencivenga, L., Cannavò, A., Corbi, G., Ferrara, N., Houser, S. R., Koch, W. J., et al. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00074 · Cited by 114
Ellis-Connell, A. L., Iempridee, T., Xu, M., & Mertz, J. E. (2010) · Journal of Virology · doi:10.1128/jvi.00923-10 · Cited by 94
“When these modified oligonucleotides duplex with specific miRNAs, the endogenous cellular RNase H degrades these miRNAs, leading to a significant reduction in their levels in cells (23).”
BackgroundRole of Dicer in female fertility
Luense, L. J., Carletti, M. Z., & Christenson, L. K. (2009) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2009.05.001 · Cited by 107
“Recently, antagomirs and locked nucleic acid oligonucleotides have been used to downregulate specific miRNA expression in a variety of cells in vitro and tissues in vivo [56, 57].”
BackgroundKocerha, J., Kauppinen, S., & Wahlestedt, C. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8066-1 · Cited by 90
Self-citationCortez‐Dias, N., Costa, M. C., Carrilho‐Ferreira, P., Silva, D., Jorge, C. M., Calisto, C., Pessoa, T., Martins, S. R., Sousa, J., da Silva, P. C., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0568 · Cited by 113
Guo, F., Han, X., Zhang, J., Zhao, X., Lou, J., Chen, H., & Huang, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109267 · Cited by 101
Raitoharju, E., Seppälä, I., Lyytikäinen, L., Viikari, J. S. A., Ala‐Korpela, M., Soininen, P., Kangas, A. J., Waldenberger, M., Klopp, N., Illig, T., et al. (2016) · Scientific Reports · doi:10.1038/srep38262 · Cited by 103
Liu, M., Liu, J., Wang, L., Wu, H., Zhou, C., Zhu, H., Xu, N., & Xie, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109347 · Cited by 85
Role of microRNAs in hepatocellular carcinoma: a clinical perspective
Negrini, M., Callegari, E., Elamin, B. K., Gramantieri, L., & Sabbioni (2013) · OncoTargets and Therapy · doi:10.2147/ott.s36161 · Cited by 83
“A few years later, Elmen et al demonstrated that inhibition of miR-122 by administration of anti-miRNA oligonucleotides in nonhuman primates was a promising approach for reducing miRNA activity in the adult liver without any evidence of toxicity.(79) These proofs of principle established the basis for the various stud…”
miRNAs link metabolic reprogramming to oncogenesis
Hatziapostolou, M., Polytarchou, C., & Iliopoulos, D. (2013) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2013.03.002 · Cited by 90
Yigit, M., Ghosh, S. K., Kumar, M., Petkova, V., Kavishwar, A., Moore, A., & Medarova, Z. (2012) · Oncogene · doi:10.1038/onc.2012.173 · Cited by 86
MicroRNAs and Multiple Sclerosis
Tufekci, K. U., Oner, M. G., Genc, S., & Genc, K. (2011) · Autoimmune Diseases · doi:10.4061/2011/807426 · Cited by 82
“oligonucleotides in studying miRNA functions in vivo and in the future development of miRNA-based therapeutics [303, 304].”
BackgroundMicroRNAs in immune regulation—Opportunities for cancer immunotherapy
Okada, H., Kohanbash, G., & Lotze, M. T. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.02.002 · Cited by 87
“The “antagomir”-mediated silencing of disease-associated miRs (Elmen et al., 2008) may be a novel and promising strategy for treatment of cancer waiting for clinical testing.”
BackgroundDifferential MicroRNA-34a Expression and Tumor Suppressor Function in Retinoblastoma Cells
Dalgard, C. L., González, M. N., deNiro, J. E., & O’Brien, J. M. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3520 · Cited by 86
FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer
Orellana, E. A., Tenneti, S., Rangasamy, L., Lyle, L. T., Low, P. S., & Kasinski, A. L. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam9327 · Cited by 96
Ohno, M., Shibata, C., Kishikawa, T., Yoshikawa, T., Takata, A., Kojima, K., Akanuma, M., Kang, Y. J., Yoshida, H., Otsuka, M., et al. (2013) · Scientific Reports · doi:10.1038/srep02553 · Cited by 85
CHO microRNA engineering is growing up: Recent successes and future challenges
Jadhav, V., Hackl, M., Druz, A., Shridhar, S., Chung, C.-Y., Heffner, K. M., Kreil, D. P., Betenbaugh, M., Shiloach, J., Barron, N., et al. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.07.007 · Cited by 85
“Application of an LNA antagomir of miR-122 leads to 25–30% reduction of plasma cholesterol levels (Elmen et al., 2008; Esau et al., 2006).”
BackgroundNon-coding RNA therapeutics for cardiac regeneration.
Braga, L., Ali, H., Secco, I., & Giacca, M. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa071 · Cited by 84
“Originally discovered through genetic screens in Drosophila, this pathway is also a broad and essential regulator of cellular proliferation and organ size in mammals.40,41 The final positive effectors of this pathway are the transcriptional co-activators yes-associated protein (YAP) and the transcriptional coactivator…”
BackgroundInfluentialRole of miR-221/222 in Tumor Development and the Underlying Mechanism
Song, Q., An, Q., Niu, B., Lu, X., Zhang, N., & Cao, X. (2019) · Journal of Oncology · doi:10.1155/2019/7252013 · Cited by 104
Basu, S., & Bhattacharyya, S. N. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku346 · Cited by 88
“This was done based on previous reports that Locked Nucleic Acids modified (LNA) antisense oligonucleotides are more effective than standard 2’-O-methyl modified oligonucleotides in binding and inhibiting miRNA action in primate, human and rat liver cells (32,50).”
Wang, W., Liu, L., Li, G., Chen, Y., Li, C., Jin, D., & Wang, X. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0307 · Cited by 87
Bhandari, A., Gordon, W., Dizon, D., Hopkin, A. S., Gordon, E., Yu, Z., & Andersen, B. (2012) · Oncogene · doi:10.1038/onc.2012.168 · Cited by 80
Exosomal miRNAs in Lung Diseases: From Biologic Function to Therapeutic Targets
Guiot, J., Struman, I., Louis, E. J., Louis, R. E., Malaise, M., & Njock, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8091345 · Cited by 87
MicroRNA-489 Induction by Hypoxia–Inducible Factor–1 Protects against Ischemic Kidney Injury
Wei, Q., Liu, Y., Liu, P., Hao, J., Liang, M., Mi, Q., Chen, J., & Dong, Z. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015080870 · Cited by 92
MicroRNA and cutaneous melanoma: from discovery to prognosis and therapy
Segura, M. F., Greenwald, H. S., Hanniford, D., Osman, I., & Hernando, E. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs205 · Cited by 86
miR-155 modulates TNF-α-inhibited osteogenic differentiation by targeting SOCS1 expression.
Wu, T., Xie, M., Wang, X.-J., Jiang, X.-Q., Li, J., & Huang, H. (2012) · Bone · doi:10.1016/j.bone.2012.05.013 · Cited by 83
“Given that targeting miRNA by antagonists and antimiRNA oligonucleotides has been tested in animal models and is currently in phase I clinical trials [40–42], our findings, together with the available platform for the design of efficient and specific antimiRNA oligonucleotides [43], suggest that miR-155 may be a poten…”
Background
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.